source
- Vivoryon reclaims Chinese rights to kidney disease drug amid cash crunchVivoryon Therapeutics, a Munich-based biotech, has taken back the rights to develop its kidney disease candidate in China after a licensing arrangement with Simcere Pharmaceuticals. The original 2…
- Podcast explores how intratumoral injections may spark systemic cancer immunityIn a recent episode of BioSpace's Denatured podcast, host Jennifer C. Smith-Parker spoke with Lewis Bender, CEO of Intensity Therapeutics, and Paul-Peter Tak, president and CEO of Candel Therapeuti…